Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
about
Rofecoxib for osteoarthritisCOX-2: where are we in 2003?--distinction from NSAIDs becoming blurredCyclooxygenase-2 in epilepsy.COX-2 inhibitors and the gastrointestinal tractCyclooxygenase inhibition: between the devil and the deep blue seaRisk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsAdvances in anti-inflammatory therapy.A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirinNon-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract.The development of COX2 inhibitors.Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side applicationAre cyclooxygenase 2 inhibitors free of gastrointestinal side effects?COX-2 inhibitors compared and contrasted.Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.Rheumatoid arthritis: developing pharmacological therapies.Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy.Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.Cancer, cyclo-oxygenase and nonsteroidal anti-inflammatory drugs - can we combine all three?Functional drug candidate profiling using complex human organotypic cell culture models: a promising way to reduce clinical drug failure.Efficacy of celecoxib for acute pain management following total hip arthroplasty in elderly patients: A prospective, randomized, placebo-control trialIn Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and Their Combined Action on Prostaglandin H Synthase-1.Celecoxib versus diclofenac in the management of osteoarthritis of the knee.Pathogenic Mechanisms and In Vitro Diagnosis of AERD.Gallic Acid Enriched Fraction of Phyllanthus emblica Potentiates Indomethacin-Induced Gastric Ulcer Healing via e-NOS-Dependent Pathway.Oxidases and oxygenases in regulation of neutrophil redox pathways in Behçet's disease patients.Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis.The different patterns of blood pressure elevation by rofecoxib and nabumetone.A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.Chondrogenesis of expanded adult human articular chondrocytes is enhanced by specific prostaglandins.Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs.In vitro studies of a degradable device for controlled-release of meloxicam.Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.DL-trans-3,4-dihydroxy-1-selenolane (DHS(red)) accelerates healing of indomethacin-induced stomach ulceration in mice.Role of the COX-independent pathways in the ulcer-healing action of epigallocatechin gallate.Subcutaneous meloxicam suspension pharmacokinetics in mice and dose considerations for postoperative analgesia.Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity.Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis.
P2860
Q24244871-FB811588-70E8-4232-AF68-7E399CA8F261Q24804373-55D5FB90-ABC8-4539-8145-5EA5B123D63FQ26827095-DB769925-8822-45B5-9F38-621AC6A13620Q28176997-A173A337-2C0C-49E2-9023-FEB6B2A6E28CQ28192790-EFC6D81B-8928-4228-A904-91744D6FC7C4Q28217824-C82C0BC5-1E9F-4C2E-8BDE-ADA41E58A3CAQ33183500-3CA67C1F-C7E1-403E-AD88-916794DC524FQ33952053-8CFF4C2E-55D8-42DF-BD74-7ECEF15DE93BQ34095700-CCF154B9-14A0-4012-A646-E49C905E5558Q34180681-7306E71C-B665-4C7A-8215-FE885975A3E3Q34361584-43551896-9E0F-48AE-9BE0-CACFE4CB8F1AQ34384868-EAC03423-822D-4D4B-A09A-B310A99EFF89Q34515513-1BA3AD52-E4B8-49B4-9190-935286C1115DQ34530950-7CC5374F-82DB-4DEB-917E-54499C3090A4Q34651032-C3B92325-70BE-4053-B0E6-4F2D2D18883CQ34706975-DA52AB39-45DE-4D89-AF4E-0F46BE55562CQ35103596-A96BA24A-63BE-4F66-ABCF-12BF5869CCB0Q35196870-630AB410-12E9-4B1C-BE9C-B5D251851C41Q35552561-B33AEABF-986D-41B6-940A-1B2A42332184Q37597583-7BA8EE05-4B02-4989-80CB-D9FBB68549DAQ38088772-1EFEC166-3E69-4B3B-B839-B49329C81709Q39180018-D362F135-B47A-41E6-91BA-4118FA5C4001Q39314986-CFA2EFA9-E7EB-4FD0-9A5A-A450F27A9AD8Q39420935-624E39E9-6F8D-4BCE-9C85-98C05E5FF073Q41898865-7DC9CEDB-52A8-4D36-887D-C165A8F6E270Q42322746-B05FD29B-EA9A-406E-9C7C-4E35C60C8312Q42490426-22665398-DBB4-4091-8496-7BF0ECEAEFA5Q43266411-478DF4D6-05A9-43D8-B17F-480459810D9FQ44010988-2105BA67-AAE1-4142-92DF-E3A7F9F7074BQ44171500-4C652F4E-40DA-4D77-8FC5-34710D2B065BQ44847821-1094690C-2788-4CC9-88C5-3AA571CCF5C4Q44869580-AB0210AF-13C1-4913-BE52-1FEFF3488869Q45868063-4E67FF94-8F44-4214-943E-CC04BE821532Q46556599-FB1B1F01-E46C-4EAE-B53B-3BE123FE4C04Q48237143-2227A86E-4E71-4168-9599-8EEFBF68D47DQ50505706-353AA2D5-A089-44B6-AD56-890882E220CEQ50516048-B8D5F040-CBED-4ECC-B374-A9ED42F83EBBQ50928647-5DE226B5-0D50-47C8-97DA-D4DAC1936CDEQ53397053-1DCA4666-BBDB-4DF0-9A3E-071D7CF0E4CCQ55055573-6BA254CC-48E5-42BA-A038-03BB3261DDD2
P2860
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@en
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@nl
type
label
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@en
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@nl
prefLabel
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@en
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@nl
P2093
P2860
P50
P356
P1433
P1476
Interpreting the clinical sign ...... genase-1 and cyclooxygenase-2.
@en
P2093
Breedveld F
Dougados M
Gijon-Baños J
P2860
P304
P356
10.1093/RHEUMATOLOGY/38.8.779
P577
1999-08-01T00:00:00Z
P6179
1018528801